183 related articles for article (PubMed ID: 21159509)
41. Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer.
Ejlertsen B; Jensen MB; Mouridsen HT;
Acta Oncol; 2014 Feb; 53(2):174-85. PubMed ID: 24219541
[TBL] [Abstract][Full Text] [Related]
42. St. Gallen endocrine response classes predict recurrence rates over time.
Koornstra RH; Beelen KJ; Vincent AD; van der Noort V; van Diest PJ; Linn SC
Breast; 2015 Dec; 24(6):705-12. PubMed ID: 26429398
[TBL] [Abstract][Full Text] [Related]
43. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer.
Love RR; Duc NB; Havighurst TC; Mohsin SK; Zhang Q; DeMets DL; Allred DC
J Clin Oncol; 2003 Feb; 21(3):453-7. PubMed ID: 12560434
[TBL] [Abstract][Full Text] [Related]
44. The prevalence of immunohistochemically determined oestrogen receptor positivity in primary breast cancer is dependent on the choice of antibody and method of heat-induced epitope retrieval - prognostic implications?
Grabau DA; Bendahl PO; Rydén L; Stål O; Fernö M;
Acta Oncol; 2013 Nov; 52(8):1657-66. PubMed ID: 23343224
[TBL] [Abstract][Full Text] [Related]
45. Direct comparisons of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptor and menopausal status.
Nomura Y; Shirouzu M; Takayama T
Breast Cancer Res Treat; 1998 May; 49(1):51-60. PubMed ID: 9694611
[TBL] [Abstract][Full Text] [Related]
46. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.
Swain SM; Wilson JW; Mamounas EP; Bryant J; Wickerham DL; Fisher B; Paik S; Wolmark N
J Natl Cancer Inst; 2004 Apr; 96(7):516-23. PubMed ID: 15069113
[TBL] [Abstract][Full Text] [Related]
47. Are symptomatic guidelines for chemotherapy appropriate to ER-positive screen-detected breast cancer (SDBC)?
Bundred NJ; Prasad R; Morris J; Knox WF; Byrne G; Cheung S; Wilson M; Lawrence G
Breast Cancer Res Treat; 2013 Apr; 138(2):359-68. PubMed ID: 21744241
[TBL] [Abstract][Full Text] [Related]
48. Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy.
Bartlett JM; Thomas J; Ross DT; Seitz RS; Ring BZ; Beck RA; Pedersen HC; Munro A; Kunkler IH; Campbell FM; Jack W; Kerr GR; Johnstone L; Cameron DA; Chetty U
Breast Cancer Res; 2010; 12(4):R47. PubMed ID: 20615243
[TBL] [Abstract][Full Text] [Related]
49. MnSOD rs4880 and XPD rs13181 polymorphisms predict the survival of breast cancer patients treated with adjuvant tamoxifen.
Tengström M; Mannermaa A; Kosma VM; Soini Y; Hirvonen A; Kataja V
Acta Oncol; 2014 Jun; 53(6):769-75. PubMed ID: 24716840
[TBL] [Abstract][Full Text] [Related]
50. Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy.
Larsen MS; Bjerre K; Giobbie-Hurder A; Lænkholm AV; Henriksen KL; Ejlertsen B; Lykkesfeldt AE; Rasmussen BB
Acta Oncol; 2012 Jul; 51(6):781-9. PubMed ID: 22462654
[TBL] [Abstract][Full Text] [Related]
51. The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities.
Jordan VC; Obiorah I; Fan P; Kim HR; Ariazi E; Cunliffe H; Brauch H
Breast; 2011 Oct; 20 Suppl 3(Suppl 3):S1-11. PubMed ID: 22015273
[TBL] [Abstract][Full Text] [Related]
52. Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Tang G; Shak S; Paik S; Anderson SJ; Costantino JP; Geyer CE; Mamounas EP; Wickerham DL; Wolmark N
Breast Cancer Res Treat; 2011 May; 127(1):133-42. PubMed ID: 21221771
[TBL] [Abstract][Full Text] [Related]
53. The role of primary endocrine therapy in older women with operable breast cancer.
Johnston SJ; Cheung KL
Future Oncol; 2015; 11(10):1555-65. PubMed ID: 25963432
[TBL] [Abstract][Full Text] [Related]
54. Systematic review of LHRH agonists for the adjuvant treatment of early breast cancer.
Sharma R; Beith J; Hamilton A
Breast; 2005 Jun; 14(3):181-91. PubMed ID: 15927827
[TBL] [Abstract][Full Text] [Related]
55. Using second harmonic generation to predict patient outcome in solid tumors.
Burke K; Smid M; Dawes RP; Timmermans MA; Salzman P; van Deurzen CH; Beer DG; Foekens JA; Brown E
BMC Cancer; 2015 Nov; 15():929. PubMed ID: 26603532
[TBL] [Abstract][Full Text] [Related]
56. Prognostic effect of estrogen receptor status across age in primary breast cancer.
Bentzon N; Düring M; Rasmussen BB; Mouridsen H; Kroman N
Int J Cancer; 2008 Mar; 122(5):1089-94. PubMed ID: 17960621
[TBL] [Abstract][Full Text] [Related]
57. Tamoxifen-induced hirsutism.
Al-Niaimi F; Lyon C
J Drugs Dermatol; 2011 Jul; 10(7):799-801. PubMed ID: 21720664
[TBL] [Abstract][Full Text] [Related]
58. Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group.
Uchino J; Samejima N; Tanabe T; Hayasaka H; Mito M; Hata Y; Asaishi K
Br J Cancer; 1994 Apr; 69(4):767-71. PubMed ID: 8142265
[TBL] [Abstract][Full Text] [Related]
59. Neo adjuvant Tamoxifen in post menopausal patients with operable breast cancer.
Salmon RJ; Remvikos Y; Campana F; Languille O; Magdalenat H; Asselain B; Clough KB;
Eur J Surg Oncol; 2003 Dec; 29(10):831-4. PubMed ID: 14624772
[TBL] [Abstract][Full Text] [Related]
60. Impact of Oncotype DX testing on adjuvant treatment decisions in patients with early breast cancer: a single-center study in the United Arab Emirates.
Jaafar H; Bashir MA; Taher A; Qawasmeh K; Jaloudi M
Asia Pac J Clin Oncol; 2014 Dec; 10(4):354-60. PubMed ID: 25243360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
